Infection with the human papillomaviruses (HPV) induces warts and is strongly associated with the development of cervical cancer. Our long-term goal is to elucidate the molecular basis for HPV-induced lesions and to develop therapeutic strategies for the elimination of HPV infection, Apoptosis is a genetically programmed process of cellular destruction that can eliminate virally infected cells or tumors. Viruses such as HPV have evolved specific gene products to modulate apoptosis. Induction of apoptosis is a desirable approach in treating HPV-induced lesions. The HPV E6 gene is essential for viral replication and induces apoptosis. However, the mechanism by which E3 mediates cellular sensitization to apoptosis remains to be determined. To understand the molecular basis for E6-mediated apoptosis, we have established human keratinocytes expressing HPV E6 and found these cells to be susceptible to apoptosis induced by chemotherapeutic agents. To identify genes responsible for E6-mediated apoptosis, a proteomic approach was taken. Significantly, the level and activity of Cdc2, the cyclin-dependent kinase required for cells to enter mitosis and whose aberrant activation has been associated with apoptosis, was increased in E6-expressing cells undergoing apoptosis. An E6 mutant that is unable to activate Cdc2 is defective in sensitizing cells to apoptosis. Moreover, inhibition of Cdc2 activity with specific inhibitor reduced ap6ptosis. We hypothesize that activation of Cdc2 plays an important role in E6-mediated cellular sensitization to apoptosis.
The specific aim of this proposal is designed to test this possibility with the following approaches: (1) to examine the relevance of Cdc2 to E6-mediated cellular sensitization to apoptosis through a genetic approach and (2) to determine the role of Cdc2 in E6-mediated apoptosis by molecular ablation and ectopic expression. These studies will help understand the mechanism of E6-mediated apoptosis and contribute to the development of therapeutic approaches against HPV-induced diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
1R03AI060829-01A1
Application #
6967225
Study Section
Special Emphasis Panel (ZRG1-IDM-G (90))
Program Officer
Hiltke, Thomas J
Project Start
2005-07-01
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$81,000
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655